NEWS - California Healthcare Institute

echinoidclapΒιοτεχνολογία

1 Δεκ 2012 (πριν από 4 χρόνια και 10 μήνες)

193 εμφανίσεις




NEWS

FOR IMMEDIATE RELEASE




Contacts:

Molly Ingraham

Thursday, November 15, 2007




858
-
551
-
6677

ingraham@chi.org

or

Nicole Beckstrand

858
-
456
-
8881

beckstrand@chi.org



TWO NEW MEMBERS ELECTED TO CALIFORNIA HEALTHCARE

INSTITUTE’S

BOARD OF DIRECTORS



LA JOLLA, CALIF., Nov. 15
, 2007

--

The California Healthcare Institute (CHI) today
announced the election of Scott Garrett, president and CEO of Beckman Coulter, Inc., and
George A. Scangos, Ph.D., president and chief ex
ecutive officer of Exelixis, to its board of
directors. CHI is a non
-
profit public policy research organization, representing leading California
academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

Scott Garrett is pr
esident and chief executive officer of Beckman Coulter, Inc., which
develops, manufactures and markets products that simplify, automate and innovate complex
biomedical tests, helping to improve patient health and reduce the cost of care. Before joining
Be
ckman Coulter in 2002, Garrett served as chief executive officer of Garrett Capital Advisors,
LLC


a company he founded in 1998. Prior to that, he spent 25 years working for Baxter
International and American Hospital Supply Corporation in a wide range of

medical device and
life sciences areas. In 1994, Garrett led the buyout of Baxter’s diagnostics business. As
chairman and chief executive officer, he built Baxter spin
-
off, Dade Behring, into one of the
world’s largest clinical diagnostics companies. Ga
rrett serves on the board of directors for
AdvaMed. He is a member of the executive advisory council of Water Street Healthcare

Partners, L.P. and the advisory board of Radius Ventures, LLC. He holds a Bachelor of Science
degree in mechanical engineering
from Valparaiso University and a Master of Business
Administration from Lake Forest Graduate School of Management.

George A. Scangos, Ph.D., is president and chief executive officer of Exelixis, a
development
-
stage biotechnology company dedicated to the d
iscovery and development of novel
small molecule therapeutics for the treatment of cancer and other serious diseases. Scangos
began his career on the faculty of the Johns Hopkins University, where he now holds an
appointment as adjunct professor of biolog
y. He left Hopkins in 1986 to work for Bayer
Corporation, where he held several positions, including senior vice president of research and
development for Bayer's pharmaceutical division, and then president of Bayer Biotechnology.
Scangos serves on the bo
ards of directors of Anadys Pharmaceuticals, Entelos, Inc., as well as
Exelixis. He serves on the board of visitors at the University of California, San Francisco School
of Pharmacy, the board of overseers at the University of California, Davis Medical Sch
ool, and
the advisory board for the Cornell University Life Sciences Initiative. Scangos received a
Bachelor of Arts degree from Cornell University, a doctorate in microbiology from the
University of Massachusetts, and was a Jane Coffin Childs Postdoctora
l Fellow in the laboratory
of Frank Ruddle at Yale University.


“As we work to advance medical innovation through responsible public policy, we strive
to bring together our industry’s top leaders to help guide the organization,” said David Gollaher,
Ph.D.,

CHI’s president and chief executive officer. “Beckman Coulter and Exelixis are at the
leading edge of life sciences R&D, and we are pleased to welcome George and Scott to our
board.”

CHI represents more than 250 leading medical device, biotechnology, dia
gnostics and
pharmaceutical companies and public and private academic biomedical research organizations.
CHI’s mission is to advance responsible public policies that foster medical innovation and
promote scientific discovery. CHI’s website is www.chi.org
.

###